TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Thu Jul 24

NL

Article

TMFBiologyFool published an article 5:01 PM

Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger

Gilead gains FDA approvela for its first cancer drug Zydelig, which will compete against Johnson & Johnson and Pharmacyclics' Imbruvica.

Wed Jul 23

NL

Article

TMFBiologyFool published an article 6:12 PM

What Will Puma Biotechnology Inc's $700 Million Man Do Next?

A sale to Johnson & Johnson, Pfizer, Roche, or one of the other big pharmas seems like the most likely outcome for Puma Biotechnology Inc.

Tue Jul 22

NL

Article

TMFBiologyFool published an article 8:03 PM

Puma Biotechnology Inc's Overnight Triple is Just the Beginning

Pfizer gives Puma Biotechnology a gift, while Puma might be able to steal sales from Roche.

NL

Article

TMFBiologyFool published an article 5:01 PM

3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call

Competition with AbbVie and Merck is important, but hepatitis C shouldn't be your sole focus.

Mon Jul 21

NL

Article

TMFBiologyFool published an article 4:07 PM

3 Quotes From Johnson & Johnson's Conference Call You Need to Read

Using cash from a divestiture, competition from Gilead and AbbVie, and a discussion of biosimilars.

NL

Article

TMFBiologyFool published an article 2:01 PM

Yellen Hates Biotech Stocks! Should You?

Are big biotechs -- Amgen, Biogen Idec, Gilead Sciences, and Celgene -- really overvalued, or is the Fed chairwoman looking at smaller companies?

Tue Jul 15

NL

Article

TMFBiologyFool published an article 5:34 PM

Time to Fall Back in Love With Exelixis Inc.?

Good news from Exelixis' partner Roche, but we don't know if the trial data is good enough to beat GlaxoSmithKline's competing regimen.

Mon Jul 14

NL

Article

TMFBiologyFool published an article 1:45 PM

Arena Pharmaceuticals Inc. Still Down After CEO's Sale

It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.

Thu Jul 10

NL

Article

TMFBiologyFool published an article 3:47 PM

3 Reasons Not to Worry About Sarepta Therapeutics Inc.

Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.

Thu Jul 3

NL

Article

TMFBiologyFool published an article 11:03 AM

3 Things to Look for in MannKind's Partnership

Merck would be a perfect partner for MannKind; Novo Nordisk and Eli Lilly are likely out.

Mon Jun 30

NL

Article

TMFBiologyFool published an article 7:10 PM

Gilead Sciences Inc.'s Upcoming Catalyst(s)

Gilead's Sciences' idelalisib will be used in combination with Roche and Biogen Idec's Rituxan. An FDA approval is key, with Infinity Pharmaceuticals hot on its heels.

NL

Article

TMFBiologyFool published an article 12:59 PM

MannKind's Afrezza Approved but Will Doctors Prescribe It?

MannKind is going to have a hard time competing with Novo Nordisk and Eli Lilly, especially in type 1 diabetics.

Fri Jun 27

NL

Article

TMFBiologyFool published an article 7:50 PM

Up 9%: What You Need to Know About MannKind Today

MannKind's Afrezza is approved but can it compete with injected insulin from Novo Nordisk and Eli Lilly?

Wed Jun 25

NL

Article

TMFBiologyFool published an article 9:35 PM

AstraZeneca plc Fails to Convince FDA Committee of Olaparib's Merit. Pfizer Next?

An FDA advisory committee recommends against accelerated approval for olaparib, potentially justifying a lower bid from Pfizer.

Tue Jun 24

NL

Article

TMFBiologyFool published an article 7:01 PM

Vertex Gets Out of TRAFFIC and TRANSPORTs Shares 40% Higher

Vertex Pharmaceuticals cystic fibrosis combination looks good enough to get approved and knock down sales of antibiotics from Gilead Sciences and Novartis.

NL

Article

TMFBiologyFool published an article 11:59 AM

AstraZeneca Gets a Chance to Prove Its Worth to Pfizer

A positive result at an FDA advisory committee for AstraZeneca's olaparib, which will compete with AbbVie's veliparib, could make the British company more attractive to Pfizer.

Mon Jun 23

NL

Article

TMFBiologyFool published an article 7:15 PM

Biotech M&A: Do We Need a New Driver?

Hepatitis C acquisitions like we've seen from Gilead, Bristol-Myers Squibb, and Merck can't last forever.

NL

Article

TMFBiologyFool published an article 6:42 PM

3 Stocks Scoring for Investors

Three health care stocks to consider for your watchlist.

NL

Article

TMFBiologyFool published an article 6:17 PM

Of These 3 Battleground Biotech Stocks, 1 Is a Buy

Do Amarin, Prosensa, and Jazz Pharmaceuticals deserve a goal, a yellow card, or a straight stay-away red card?

NL

Article

TMFBiologyFool published an article 5:57 PM

Biotech 101: Off-Label Prescriptions

Investors can learn something from Medivation, GlaxoSmithKline, Amarin and AstraZeneca.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 97.17
Player Rank 2126 out of 74997
Score 1585.28
Score Change Today -16.78
Accuracy 66.35%
Active Picks 74
Total Picks 213
Best Pick MYL (+278.48)
Worst Pick SHPG (-420.97)
Average Score per Pick 7.44
Charms Earned 9
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts